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Background: Primordial dwarfism is a state of extreme prenatal and postnatal growth deficiency, and is
characterized by marked clinical and genetic heterogeneity.
Results: Two presumably unrelated consanguineous families presented with an apparently novel form of primordial
dwarfism in which severe growth deficiency is accompanied by distinct facial dysmorphism, brain malformation
(microcephaly, agenesis of corpus callosum, and simplified gyration), and severe encephalopathy with seizures.
Combined autozygome/exome analysis revealed a novel missense mutation in WDR4 as the likely causal variant. WDR4
is the human ortholog of the yeast Trm82, an essential component of the Trm8/Trm82 holoenzyme that effects a
highly conserved and specific (m7G46) methylation of tRNA. The human mutation and the corresponding yeast
mutation result in a significant reduction of m7G46 methylation of specific tRNA species, which provides a potential
mechanism for primordial dwarfism associated with this lesion, since reduced m7G46 modification causes a growth
deficiency phenotype in yeast.
Conclusion: Our study expands the number of biological pathways underlying primordial dwarfism and adds to a
growing list of human diseases linked to abnormal tRNA modification.Background
Primordial dwarfism (PD) is a term used to describe a
wide range of phenotypes that have in common severe
prenatal growth deficiency (>3 SD below the mean) that
persists postnatally [1]. Although extremely rare, the
monogenic nature of PD lends itself readily to gene
mapping approaches thus representing a unique re-
source for understanding the biological networks that
control growth through the discovery of genes that are
mutated in this condition [2].
Impaired DNA damage repair is among the earliest
identified mechanisms in PD as revealed by the discovery
that ATR is mutated in patients with Seckel syndrome, a
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voked in PD caused by mutations in ATRIP, BRCA2,
DNA2, and XRCC4 [4, 5]. Impaired mitosis due to cen-
trosomal abnormalities has now emerged as a major
mechanism underlying many forms of PD [2, 6–9]. Less
common forms of PD were found to be caused by
mutations in genes involved in replication licensing,
splicing and serine synthesis [10–13]. Despite the re-
markable acceleration of PD disease gene discovery in
recent years, one-third of the cases remain undiagnosed
molecularly, which suggests that additional disease
genes likely exist and these might further expand the
known molecular network that controls growth [4].
tRNA is a well-studied class of non-coding RNA that
plays an essential role in protein synthesis by transfer-
ring amino acids to the growing peptide chain as the
corresponding mRNA is being decoded by the riboso-
mal translational machinery. A remarkable multitude of
modification reactions (>100) are known, which are
often highly conserved in different organisms, includingle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Shaheen et al. Genome Biology  (2015) 16:210 Page 2 of 11in prokaryotes and archaea, clearly suggesting their im-
portance [14]. Our knowledge of the biology of tRNA
modification comes primarily from work on the yeast
Saccharomyces cerevisiae and other model organisms
[15–17]. In general, modifications in the tRNA anti-
codon loop are critical for translational efficiency,
frame maintenance, and fidelity, and lack of these mod-
ifications often leads to lethality, slow growth, and/or
other phenotypic effects [16, 18]. Modifications to the
body of the tRNA are generally involved in tRNA fold-
ing and stability [19–22], and lack of any of several dif-
ferent body modifications in yeast causes temperature
sensitivity due to rapid tRNA decay (RTD) of specific
tRNAs [23–25].
The recent identification of several links between
tRNA modification and human disease have spurred in-
creased interest in this field and its potential to explain
the pathogenesis of clinically relevant disorders [26]. In
this study, we describe an apparently novel clinical
condition characterized by primordial dwarfism and a
unique set of additional features. We show that the two
families affected by this disorder map to WDR4, the hu-
man ortholog of Trm82, which is required for formation
of the highly conserved m7G46 (7-methylguanosine)
modification of tRNA. The m7G46 modification occurs
widely in prokaryotes and eukaryotes [14], and in S.
cerevisiae requires a holoenzyme comprised of the
Trm8 methyltransferase subunit and its WD40 repeat-
containing binding partner Trm82 [27], which appears
to be involved in maintaining Trm8 levels [28], and in
helping Trm8 maintain an active conformation [29].
Yeast trm82Δ mutants, like trm8Δ mutants, are mildly
temperature sensitive due to lack of m7G in their tRNA
[28], and have synthetic genetic interactions with trm4Δ
mutants (lacking m5C), and a number of other modifi-
cation mutants, resulting in a severe temperature sensi-
tive growth defect [23]. Human WDR4 and METTL1
are the likely orthologs of S. cerevisiae TRM82 and
TRM8 based on homology, and on their complementa-
tion of yeast mutants lacking m7G46 [27]. Here we
show that the WDR4 mutation affects m7G46 methyla-
tion suggesting a potential mechanism for this novel
form of PD.
Results
Identification of a novel PD syndrome
Patient 1 (14DG1157)
This female infant was born to a 20-year-old mother and
26-year-old father by normal vaginal delivery at 37-
weeks’ gestation. The parents are healthy first cousins
(Fig. 1a). The family history is non-contributory. The
couple had a subsequent boy who died a few days after
birth because of growth retardation and multiple congeni-
tal heart anomalies. During the gestation of patient 1, thepregnancy was complicated by threatened abortion in the
first trimester. Intrauterine growth retardation and weak
fetal movements were also documented. The birth weight
was 1,600 g. The birth length and head circumference
were not recorded but mentioned to be small. She was re-
ferred to the Clinical Genetics Department at the age of
4 months because of poor gain of weight and for genetic
counseling. On clinical examination she was noted to have
a head circumference of 31.5 cm (−5 SD) weight of
2,800 g (−6 SD), and length of 48 cm (−5 SD). The patient
had a high forehead, prominent eyes, depressed nasal
bridge, short philtrum, tented upper lip and bulged alveo-
lar ridge, and prominent ear lobule (Fig. 1b).
Her neurological evaluation revealed hypertonia, brisk
deep-tendon reflexes, with flexor plantar responses. At
that age, radiological examination showed unossified
pubic bones, proportionately short femora, and broad
metaphyses of the femora and tibiae. The tibiae and
fibulae were short and equal in length.
At the age of 10 months, she developed seizures with
only partial response to valproate and lamotrigine. EEG
records revealed low voltage slow waves (3–6 cycles/s)
mixed with sleep spindle.
At the age of 20 months, her weight, length, and head
circumference were 3,500 g (−6.5 SD), 55 cm (−9.5 SD),
and 32 cm (−10.7 SD), respectively. The girl was spastic
with contracture deformity in the elbows and hands. Her
neurological evaluation revealed hypertonia, brisk deep-
tendon reflexes, with flexor plantar responses. She had
not acquired any developmental milestones and never
recognized her mother. Abdominal ultrasonography and
echocardiography showed normal results. Ophthalmo-
logical examination showed bilateral optic atrophy.
Chromosomal examination from peripheral blood lym-
phocytes and high resolution banding technique revealed
normal female karyotype 46,XX.
Cranial MRI showed partial agenesis of corpus callosum,
and abnormal gyral pattern most pronounced posteriorly.
Diagnosis of microcephalic primordial dwarfism was made
at this time based on significant pre- and post-natal growth
retardation. Because of the partial overlap with microceph-
alic osteodysplastic primordial dwarfism I, analysis of
RNU4ATAC was undertaken but revealed negative results.
Patient 2 (14DG1160)
Patient 2 was the fifth child born to a 36-year-old
mother and 39-year-old father. The parents are maternal
and paternal first cousins (double consanguineous)
(Fig. 1a). The second pregnancy resulted in a similarly
affected boy who died at the age of 9 months because of
pneumonia accompanied by uncontrolled seizures. A
postmortem examination was not performed. There was
no other family history of note. Patient 2 was delivered
vaginally weighing 1,500 g (−3.7 SD) at 38 weeks’
Fig. 1 Identification of a novel PD syndrome. a Family pedigree of 14DG1157 & 14DG1160 showing the consanguineous nature of the parents.
The index is indicated in each pedigree by an arrow, and asterisks denote individuals whose DNA was available for analysis. b, c Facial images for
the index of each family showing the highly similar dysmorphic profile consisting of high forehead, prominent eyes, depressed nasal bridge,
short philtrum, tented upper lip and bulged alveolar ridge, and prominent ear lobule. d–g MRI image of 14DG1160 showing partial agenesis of
corpus callosum, and abnormal gyral pattern most pronounced posteriorly
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not recorded. At age 4 months she experienced focal sei-
zures that later evolved into generalized tonic-clonic sei-
zures controlled by combination sodium valproate,
levetiracetam, and lamotrigine therapy. EEG records re-
vealed high voltage delta waves (2–4 cycles/s). Abdominal
ultrasonography and echocardiography showed normal
results.
At the age of 7 months, she was referred to our Clinical
Genetics Department because of the microcephaly and
poor weight gain for genetic counseling. On examination,
her weight, length and head circumference were 4,200 g
(−4.7 SD), 53 cm (−5.7 SD), and 33.2 cm (−7 SD), respect-
ively. Her facial features were quite similar to patient 1
showing rounded face with high forehead, prominent eyes,
depressed nasal bridge, short philtrum, bow shaped
mouth, and prominent alveolar ridge (Fig. 1c). Her neuro-
logical evaluation revealed hypertonia, brisk deep-tendon
reflexes, with flexor plantar responses. Ophthalmological
examination showed bilateral optic atrophy.
She presented at the age of 9 months with high fever
and chest infection that diagnosed as pneumonia. This
was accompanied by status epilepticus and she went into
coma for 30 days.Follow-up at the age of 17 months, her weight, length,
and head circumference were 6,500 g (−3.8 SD), 60 cm
(−6.7 SD), and 34.5 cm (−8.9 SD), respectively. The girl
made almost no developmental progress and could not
recognize the surroundings. Oro-dental examination
showed thick alveolar ridge more in the upper than
lower and high arched palate.
Routine biochemical and metabolic screening parame-
ters were within normal ranges.
Chromosomal examination from peripheral blood lym-
phocytes and high resolution banding technique revealed
normal female karyotype 46,XX. Radiographic examin-
ation of the long bones showed proportionately short
long bones with broad metaphyses.
Cranial MRI showed partial agenesis of corpus callo-
sum, and abnormal gyral pattern most pronounced pos-
teriorly (Fig. 1d–g).
No developmental progress was observed on the last
examination of both patients. They were not able to raise
their heads or roll, and never laughed. They were unable
to follow visually, recognize their mothers, or make eye-
to-eye contact. There were no vocalizations beyond an
infrequent moaning when in discomfort. Patient 2 some-
times required a tube feeding at the age of 9 months.
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WDR4
Although the two families have different surnames, they
come from the same geographic location in Egypt, raising
the possibility of a founder mutation. Indeed, autozygosity
mapping and haplotype analysis revealed a single shared
homozygous haplotype between the two available patients
(chr21:43,809,418-44,828,031 (GRCh37/hg19)) spanning
14 RefSeq genes (Fig. 2a). Whole exome sequencing
(WES) was performed separately on each index and the
resulting variants were filtered based on frequency (novel
or <0.0001), zyogsity (homozygous), position (within the
autozygome of the corresponding samples), and nature
of the variant (coding/splicing, excluding synonymous
changes and those predicted to be benign by two inde-
pendent in silico prediction tools). Although each index
had a few variants that survived these filters, only one vari-
ant was shared by the two (WDR4, NM_033661.4:c.509G >
T; p.Arg170Leu) (Fig. 2b, c, Additional file 1: Table S1).Fig. 2 A novel PD syndrome is linked to a founder mutation in WDR4. a A
Family 1, Individual II:6 in Family 2 denoted by black lines (boxed in green
survived variants in each step in both c Sequence chromatograms of the m
the mutation is denoted by an arrow) and its location indicated in WD rep
multisequence alignment of the mutated reside (p.Arg170) showing high cReassuringly, this variant was also within the single shared
homozygous haplotype, that is, this is the only novel
coding/splicing homozygous variant within the critical
locus (Additional file 2: Table S2). Segregation analysis
using available family members confirmed that only the
two patients were homozygous. This mutation is absent in
615 in-house Saudi exomes, 1000 Genomes, Exome Server,
and ExAC Browser. It is predicted to be pathogenic by
PolyPhen (0.993), SIFT (0), and CADD (PHRED: 20.3).
Yeast trm82-K223L mutants have decreased levels of
m7G46 on tRNA
We reasoned that homozygosity of the WDR4-R170L al-
lele would result in defective m7G46 modification of tRNA,
since WDR4 is the likely human ortholog of S. cerevisiae
Trm82 [27], since the corresponding residue in other eu-
karyotes is almost always an arginine and occasionally a
lysine, since this residue is within the most highly con-
served region of the Trm8/WDR4 family (Fig. 2c), andutoSNPa showing the shared haplotype between individual II:2 in
lines). b illustration to the exome filtering scheme and the number of
utation (control tracing is shown for comparison and the location of
eat domain 4 on a schematic of WDR4. Also shown is the
onservation down to Danio rerio (boxed in green)
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R170 in human WDR4) forms a salt bridge with residue
E204 of Trm8 that is speculated to be important for main-
taining Trm8 in an active conformation (Fig. 3a) [29]. We
therefore used S. cerevisiae as a model to analyze the
effects of the WDR4-R170L mutation. We generated a
low copy (CEN) plasmid expressing the S. cerevisiae
trm82-K223L from its native promoter (CEN LEU2
PTRM82-trm82-K223L) to test its ability to complement
an S. cerevisiae trm82Δ mutant in a trm4Δ background, to
amplify the growth defects of the trm82Δ mutation
[23, 28]. We also generated plasmids bearing a
trm82-K223R variant to determine if, as expected, ar-
ginine and lysine residues are interchangeable at this
location, and a trm82-K223E variant to test the effects
of completely abrogating the salt bridge.Fig. 3 The WDR4-R170L mutation results in decreased levels of m7G on tRN
Trm8-Trm82 crystal structure. Representation of S. cerevisiae Trm8-Trm82 ho
and Trm8 is in dark gray with residue E204 in blue. Corresponding WDR4 a
PTRM82-trm82-K223L) strain has a growth defect at high temperature. Wild ty
variants as indicated were grown overnight in S -Leu medium containing d
diluted 10-fold in H2O, and then 2 μL was spotted onto indicated media, fo
tRNAPhe purified from human LCLs derived from a PD patient homozygous
the WDR4-R170L proband with PD, and from control LCLs, was digested to
and MethodsWe found that expression of trm82-K223L suppressed
the growth defect of the trm82Δ trm4Δ strain at temper-
atures up to 37 °C on rich (YP + dextrose) or minimal
medium (S -Leu + dextrose), but not at 39 °C (Fig. 3b),
indicating that the Trm82-K223L variant is defective for
function at high temperature, but is not a complete loss-
of-function mutation. By contrast, expression of trm82-
K223E did not suppress the growth defect of a trm82Δ
trm4Δ strain at any temperature, consistent with a null
phenotype, whereas expression of trm82-K223R sup-
pressed the defect at all temperatures (Fig. 3b), demon-
strating that arginine and lysine are interchangeable at
this residue.
To determine the extent to which m7G levels were af-
fected in the trm82-K223L mutant (trm82Δ (CEN LEU2
PTRM82-trm82-K223L)), we analyzed modification levelsA. a Predicted location of R170 residue of WDR4, based on the yeast
loenzyme (PDB 2VDU), Trm82 is light gray with residue K223 in red,
nd METTL1 residues are in brackets. b A trm82Δ trm4Δ (CEN LEU2
pe and trm82Δ trm4Δ strains with (LEU2) plasmids expressing TRM82
extrose, diluted to OD600 of approximately 0.5 in H2O, and serially
llowed by incubation for 3 days as indicated. c Nucleoside analysis of
for the WDR4-R170L allele. tRNAPhe isolated from LCLs derived from
nucleosides and analyzed by HPLC as described in Materials
Shaheen et al. Genome Biology  (2015) 16:210 Page 6 of 11of two of the 11 yeast tRNA species known to have m7G
after growth at 30 °C or 37 °C, by purification of the cor-
responding tRNA species from bulk RNA, followed by
nuclease digestion and analysis of nucleosides by HPLC.
Strikingly, we found that tRNAPhe from the trm82-
K223L mutant had no detectable m7G after growth at
37 °C, but only mildly reduced m7G levels after growth at
30 °C, compared to levels in the wild type or the trm82-
K223R controls (0.21 moles/mole vs. 0.34 or 0.32, respect-
ively; Table 1). Other modifications of tRNAPhe were
unaffected in the trm82 mutants. By contrast, we observed
a milder reduction in m7G levels of tRNAVal(AAC) from the
trm82-K223L strain after growth at 37 °C, compared to
that from the wild type or trm82-K223R controls (0.25
moles/mole vs. 0.50 and 0.55, respectively; Table 1), and
no obvious reduction in m7G levels of tRNAVal(AAC) when
strains were grown at 30 °C (0.45 moles/mole vs. 0.53 and
0.46, respectively; Table 2). The temperature-sensitive
reduction in m7G levels found on both tRNAPhe and
tRNAVal(AAC) from the trm82-K223L mutant is con-
sistent with its temperature sensitive complementation
of a trm82Δ trm4Δ strain (Fig. 3b).
We note that growth of the trm82Δ and trm82-K223L
strains at 37 °C resulted in substantially increased levels
of m5C on tRNAVal(AAC) (Table 2), similar to the increase
in m5C levels observed previously when wild type cells
were grown under stress conditions [30–32]. Unexpect-
edly, tRNAVal(AAC) in the trm82Δ mutant also had ac-
quired an m2G modification (0.54 and 0.45 moles/mole
at 30 °C and 37 °C, respectively, compared to barely
detectable levels in the wild type strain). Since
tRNAVal(AAC) in the trm82-K223L strain acquired
0.17 moles/mole m2G at 37 °C relative to wild typeTable 1 HPLC analysis of tRNAPhe nucleoside content from an S. cer
Mod. Mol. exp. wt (CEN vec) trm82Δ (CEN TRM82) trm82Δ
30 °C
m7G 1 0.41 ± 0.04 0.34 ± 0.03 <0.03
Ψ 2 2.09 ± 0.06 1.94 ± 0.03 1.85 ±
Cm 1 0.89 ± 0.09 0.92 ± 0.05 0.93 ±
Gm 1 0.72 ± 0.01 0.76 ± 0.07 0.76 ±
m5C 2 1.53 ± 0.06 1.64 ± 0.07 1.69 ±
m2G 1 0.78 ± 0.02 0.83 ± 0.04 0.87 ±
37 °C
m7G 1 0.37 ± 0.03 0.21 ± 0.03 <0.03
Ψ 2 2.00 ± 0.08 1.91 ± 0.06 1.87 ±
Cm 1 0.98 ± 0.08 1.00 ± 0.14 0.91 ±
Gm 1 0.77 ± 0.03 0.84 ± 0.02 0.91 ±
m5C 2 1.63 ± 0.03 1.69 ± 0.02 1.79 ±
m2G 1 0.82 ± 0.05 0.88 ± 0.02 0.90 ±
Mean and standard deviation based on three individual growths and RNA preparat(from 0.10 to 0.27 moles/mole) while m7G levels were re-
duced by 0.25 moles/mole (from 0.50 to 0.25), we specu-
late that m2G levels inversely correlate with m7G levels on
this tRNA. Other tRNAVal(AAC) modifications (pseudo-
uridine, inosine, and m1G) were unaffected by the trm82
mutations (Table 2).
Cells derived from a patient homozygous for the WDR4-
R170L allele have decreased levels of m7G on tRNA
To further define the defect of the WDR4-R170L allele
and its relationship to PD, we analyzed the m7G levels in
tRNAVal(AAC) and tRNAPhe purified from lymphoblastoid
cell lines (LCLs) derived from the PD patient 1
(14DG1160), as well as from control LCLs derived from
the healthy mother (heterozygous) and a healthy brother
(homozygous wild type WDR4). We found a substantial
decrease in m7G on tRNAPhe from the PD LCL (0.08
moles/mole in the WDR4-R170L homozygote vs. 0.49
and 0.46 for the homozygous wild type WDR4 LCL and
the heterozygous LCL, respectively; Fig. 3c; Table 3),
similar to m7G levels in tRNAPhe from the correspond-
ing yeast trm82-K223L mutant (Table 1). By contrast,
levels of the control tRNAPhe modifications Cm, Gm,
m2G, pseudouridine, and m5C modifications were simi-
lar in all of the LCLs. We also observed a minor reduc-
tion of m7G on tRNAVal(AAC) (0.35 moles/mole in the
WDR4-R170L homozygote vs. 0.52 and 0.46 for the
wild type WDR4 homozygote and heterozygotes, re-
spectively; Table 3), with similar amounts of each of
four control modifications observed in the three differ-
ent LCLs. Thus, our results strongly suggest that the
WDR4-R170L mutation causes defects in m7G46 modifi-
cation in the PD patients.evisiae trm82Δ strain expressing TRM82 variants
(CEN vec) trm82Δ (CEN trm82-K223L) trm82Δ (CEN trm82-K223R)
0.21 ± 0.01 0.32 ± 0.04
0.04 1.99 ± 0.07 2.06 ± 0.05
0.08 0.95 ± 0.03 0.93 ± 0.06
0.03 0.73 ± 0.08 0.75 ± 0.02
0.03 1.66 ± 0.06 1.59 ± 0.03
0.02 0.83 ± 0.04 0.82 ± 0.03
<0.03 0.18 ± 0.02
0.01 1.82 ± 0.10 1.92 ± 0.01
0.02 0.93 ± 0.05 0.90 ± 0.04
0.05 0.96 ± 0.02 0.84 ± 0.02
0.05 1.76 ± 0.04 1.71 ± 0.02
0.07 0.94 ± 0.06 0.86 ± 0.02
ions
Table 2 HPLC analysis of tRNAVal(AAC) nucleoside content from an S. cerevisiae trm82Δ strain expressing TRM82 variants
Mod. Mol. exp. wt (CEN vec) trm82Δ (CEN TRM82) trm82Δ (CEN vec) trm82Δ (CEN trm82-K223L) trm82Δ (CEN trm82-K223R)
30 °C
m7G 1 0.50 ± 0.07 0.53 ± 0.03 <0.03 0.45 ± 0.05 0.46 ± 0.07
Ψ 4 3.66 ± 0.10 3.87 ± 0.18 3.94 ± 0.18 3.89 ± 0.15 3.64 ± 0.08
I 1 0.76 ± 0.02 0.85 ± 0.07 0.91 ± 0.06 0.90 ± 0.05 0.77 ± 0.01
m5C 1 0.87 ± 0.03 0.94 ± 0.03 1.14 ± 0.05 0.97 ± 0.05 0.91 ± 0.03
m1G 1 0.81 ± 0.05 0.98 ± 0.05 0.99 ± 0.05 1.00 ± 0.08 0.83 ± 0.05
m2G 0 0.03 ± 0.01 0.05 ± 0.01 0.54 ± 0.10 0.07 ± 0.02 0.05 ± 0.01
37 °C
m7G 1 0.61 ± 0.04 0.50 ± 0.07 <0.03 0.25 ± 0.03 0.55 ± 0.11
Ψ 4 3.88 ± 0.10 3.93 ± 0.05 3.85 ± 0.15 3.99 ± 0.20 4.10 ± 0.08
I 1 0.80 ± 0.01 0.77 ± 0.02 0.74 ± 0.06 0.78 ± 0.07 0.85 ± 0.04
m5C 1 1.04 ± 0.04 1.19 ± 0.04 1.53 ± 0.08 1.42 ± 0.09 1.16 ± 0.07
m1G 1 0.87 ± 0.01 0.79 ± 0.03 0.79 ± 0.10 0.87 ± 0.06 0.94 ± 0.01
m2G 0 0.05 ± 0.03 0.10 ± 0.03 0.45 ± 0.03 0.27 ± 0.05 0.06 ± 0.01
Mean and standard deviation based on three individual growths and RNA preparations
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Our results demonstrate a clear temperature sensitivity in
yeast caused by the trm82-K223L mutation, as reflected
by m7G levels in both tRNAPhe and tRNAVal(AAC), and a
clear importance of the identity of residue 223, based on
the complete lack of complementation of a trm82-K223E
mutant. These results cause us to speculate that the
Trm82-K223 variant might itself be temperature sensitive,
or have a temperature sensitive interaction with Trm8,
through the salt bridge described between K223 of
Trm82 and E204 of Trm8 [29]. It also seems highly
likely that the WDR4-R170L allele encodes a protein
with similar biochemical properties to the Trm82-
K223L variant, based on the high degree of conserva-
tion between these regions of Trm82 and WDR4, asTable 3 HPLC analysis of tRNAPhe and tRNAVal(AAC) nucleoside conte
Mod. Mol. exp. WDR4/WDR4
tRNAPhe
m7G 1 0.49 ± 0.10
Ψ 4 3.52 ± 0.06
Cm 1 0.71 ± 0.10
Gm 1 0.71 ± 0.07
m5C 1 0.61 ± 0.06
m2G 1 0.78 ± 0.05
tRNAVal(AAC)
m7G 1 0.52 ± 0.08
Ψ 3 3.10 ± 0.08
I 1 0.40 ± 0.03
m5C 2 1.66 ± 0.09
m2G 1 0.90 ± 0.09
Mean and standard deviation based on three individual growths and RNA preparatwell as the similarly reduced levels of m7G modifica-
tion in the WDR4-R170L LCLs.
Several human disorders have been associated with
perturbation of tRNA modification, although the level of
evidence in support of causal links varies. For example,
several tRNA modification genes have been found to be
significantly dysregulated in various cancers and some
have even been used as specific biomarkers, for example,
TRMT2A in breast cancer [33]. Associations between
variants in genes involved in tRNA modifications and
some phenotypes have been reported, for example, ELP4
and epilepsy, and IKBKAP and bronchial asthma [34, 35].
A more directly causal connection was established for sev-
eral Mendelian disorders. We previously reported that a
point mutation in ADAT3 causes intellectual disabilitynt from human LCLs
WDR4/wdr4-R170L wdr4-R170L/wdr4-R170L
0.46 ± 0.14 0.08 ± 0.02
3.82 ± 0.15 3.53 ± 0.15
0.73 ± 0.02 0.86 ± 0.03
0.63 ± 0.20 0.70 ± 0.17
0.63 ± 0.04 0.88 ± 0.04
0.66 ± 0.02 0.68 ± 0.05
0.46 ± 0.02 0.35 ± 0.06
3.07 ± 0.11 2.94 ± 0.16
0.39 ± 0.01 0.33 ± 0.04
1.70 ± 0.09 1.58 ± 0.20
0.87 ± 0.11 0.76 ± 0.01
ions
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which is the non-catalytic subunit of the complex required
for I34 modification of substrate tRNAs [37]. Thus, the as-
sociation of WDR4 with PD is the second report of a mu-
tation in the non-catalytic subunit of a tRNA modification
enzyme that results in disease. More closely related to the
PD phenotype we report in this paper are previously re-
ported mutations in TRM10A, the likely human homolog
of yeast TRM10 required for m1G9 modification [38],
which cause microcephaly and short stature [39, 40]. Simi-
larly, mutations in human NSUN2, which is required for
m5C modification of body residues 48, 49, and 50 in mam-
mals, as well as C34 of the anticodon [41, 42], cause vari-
able phenotypes that include microcephaly as a feature
[41, 43].
The pathogenesis of Mendelian diseases caused by
tRNA modification genes remains unclear but the predi-
lection to CNS involvement [26, 44] raises interesting
possibilities about the vulnerability of the brain to any
perturbation in the tight regulation of tRNA modifica-
tion and, presumably, the consequences of such perturb-
ation on protein synthesis. The mutation we previously
reported in ADAT3, for example, is now the single most
common cause of autosomal recessive intellectual dis-
ability in Saudi Arabia [45]. In this regard, the neuro-
logical phenotype we observed in patients with WDR4
mutation (severe microcephaly, agenesis of corpus callo-
sum, and lissencephaly) appears to follow the same pat-
tern of bias towards brain involvement.
Severe growth deficiency in the syndrome we describe
is not limited to the brain but rather generalized, result-
ing in microcephalic primordial dwarfism. It is unclear if
this phenotype is caused by reduced proliferation, in-
creased apoptosis or a combination of the two. Our find-
ing that LCLs derived from a PD patient homozygous
for the WDR4-R170L allele had drastically reduced levels
of m7G in their tRNAPhe and modestly reduced m7G in
their tRNAVal(AAC) strongly suggests that defective modi-
fication is a major contributor to the disease pathogen-
esis in these patients. However, it is not clear if the PD is
caused specifically by the m7G defects in tRNAPhe and/
or tRNAVal(AAC), by defects in one or more of the other
five human tRNA species known to have m7G46 [14], or
by defects in other uncharacterized tRNA species. We
note that yeast mutants lacking modifications often have
growth defects due to only a subset of the tRNA species
lacking those modifications [46].
The reduction in m7G levels in human tRNAs might
result in degradation of one or more specific tRNA spe-
cies, resulting in reduced or aberrant translation. Yeast
mutants lacking m7G, or m7G and m5C, in their tRNA
are temperature sensitive for growth due to 5'-3' exonu-
cleolytic degradation of tRNAVal(AAC) by the RTD path-
way, which degrades the tRNA because of its moreexposed 5' end [23–25]. Similarly, HeLa cells treated
with siRNA to METTL1 and NSUN2 to reduce m7G and
m5C modification undergo loss of tRNAVal(AAC) and an
accompanying loss of cell viability upon 5-fluorouracil
treatment [47]. Reduced levels of specific tRNA species
due to reduced m7G levels would be expected to lead to
defects in translation and/or reduced growth. However,
it is not known if there are other translation effects spe-
cifically due to reduced levels of m7G on tRNA, as has
been reported for some modifications in the anticodon
loop under certain growth conditions [48].
Conclusion
Our demonstration that PD patients with the WDR4-
R170L missense mutation have defects in m7G levels on
tRNA adds to the list of nine known or predicted hu-
man modification genes for which mutations have
been strongly linked to human disease or pathologies
[36, 39–41, 43, 49–60]. The underlying molecular causes
of these disease associations, and why specific modification
defects appear to result in specific disease manifestations
remains to be determined. Interestingly, there are forms of
microcephalic PD caused by impaired splicing [10], pre-
sumably resulting in impaired protein synthesis, and this
may also be invoked as a potential mechanism in PD pa-
tients with abnormal tRNA modification although future
research will be required to investigate that possibility.
Materials and methods
Human subjects
PD was defined as growth parameters >3 SD below the
mean at birth that persist postnatally. Patients were en-
rolled only after their parents signed a written informed
consent form under an IRB-approved protocol (KFSHRC
RAC#2080006). Venous blood was collected in EDTA
tubes and, when possible, in sodium heparin tubes for
DNA extraction and LCL establishment, respectively.
The research was carried out in accordance with the
principles of the Declaration of Helsinki.
Autozygosity mapping and exome sequencing
Autozygosity mapping was performed as described be-
fore [61]. Briefly, genomewide genotyping using Axiom
SNP chip array was followed by mapping of runs of
homozygosity (ROH) >2 Mb in size as surrogates of
autozygosity using AutoSNPa [62], which also delineates
the haplotype structure thus allowing the detection of
haplotype sharing across families. Exome capture was
performed using TruSeq Exome Enrichment kit (Illu-
mina) following the manufacturer’s protocol. Samples
were prepared as an Illumina sequencing library, and in
the second step, the sequencing libraries were enriched
for the desired target using the Illumina Exome Enrich-
ment protocol. The captured libraries were sequenced
Shaheen et al. Genome Biology  (2015) 16:210 Page 9 of 11using Illumina HiSeq 2000 Sequencer. The reads were
mapped against UCSC hg19 (http://genome.ucsc.edu/)
by BWA (http://bio-bwa.sourceforge.net/). The SNPs
and Indels were detected by SAMTOOLS (http://
samtools.sourceforge.net/). Variants from WES were
filtered such that only novel (or very low frequency
0.1 %), coding/splicing, homozygous variants that are
within the autozygome of the affected fetus and are
predicted to be pathogenic were considered as likely
causal variants [63]. Frequency of variants was deter-
mined using publically available variant databases (1000
Genomes, Exome Variant Server, and ExAC) as well as a
database of 630 in-house ethnically-matched exomes.
Pathogenicity was likely if the mutation is loss of function
(splicing/truncating) or, in the case of missense/in-frame
indels, removes a highly conserved amino acid and is pre-
dicted to be pathogenic by the three in silico prediction
modules PolyPhen, SIFT, and CADD.
Yeast strains and plasmids
Wild-type BY4741 (MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0),
its trm82Δ::kanMX derivative, and the homozygous
trm82Δ::natMX trm4Δ::kanMX diploid (AA0176) were
described previously [23], as was the (CEN LEU2 PTRM82-
TRM82) plasmid (AVA0279). Plasmids expressing the S.
cerevisiae TRM82-K223L (pMG569A), TRM82-K223R
(pMG570A), and TRM82-K223E (pMG571A) variants were
generated by QuickChange PCR according to manufac-
turer’s instructions (Stratagene), and the variant gene was
then ligated into the original parent vector to eliminate mu-
tations in the vector that could be introduced by PCR. All
plasmids were confirmed by sequencing before use.
Isolation and purification of tRNA from human and yeast
cells
LCLs were grown at 37 °C in 5 % CO2 in RPMI 1640
medium containing FBS (15 %), penicillin (1 U/mL),
streptomycin (1 μg/mL), and amphotericin b (0.5 μg/mL)
to a density of approximately 1.0 × 106 cells/mL, and bulk
RNA from approximately 3.6 × 108 cells was extracted
with TRIzol (Life Technologies) according to manufactur-
er's instructions. S. cerevisiae strains were grown at indi-
cated temperatures to mid-log phase in synthetic (S)
dropout media containing dextrose, and bulk low molecu-
lar weight RNA was extracted from 300 OD-mL pellets as
previously described [38]. For purification of individual
tRNAs, appropriate 5’ biotinylated oligonucleotides were
used to first purify tRNAPhe from RNA preparations as
previously described [38], followed by purification of
tRNAVal(AAC) from the remaining bulk RNA.
HPLC analysis of tRNA
Purified tRNA was digested with P1 nuclease and phos-
phatase as previously described [38], and nucleosideswere subjected to HPLC analysis at pH 7.0 as previously
described [64].
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